OXYGEN, USP (nitrogen) by Advanced Solutions Life Sciences. Approved for critical illness, hypoxia. First approved in 2013.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
OXYGEN, USP is a gaseous pharmaceutical formulation of oxygen administered via inhalation for the treatment of critical illness and hypoxia. The product is a respiratory gas therapeutic with no defined mechanism of action in traditional pharmacological terms, functioning as a life-sustaining respiratory support agent. It is approved for patients requiring supplemental oxygen therapy in acute and chronic hypoxic conditions.
Product is at peak lifecycle stage with established market presence; team size and growth trajectory dependent on Advanced Solutions Life Sciences' strategic focus and competitive positioning in respiratory therapeutics.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Comparison of Topical 5%Potassium Hydroxide vs Liquid Nitrogen in the Treatment of Plane Warts
Comparisom of Liquid Nitrogen and Vitamin D3 in The Treatment of Cutaneous Warts
Efficacy and Safety of SmofKabiven Extra Nitrogen for Parenteral Nutrition in Patients Receiving Intensive Care
Reaching Protein Target With SmofKabiven® Extra Nitrogen vs Olimel N9E During the Early Phase of Acute Critical Illness
The Impact of Low Calorie and Low Nitrogen Parenteral Nutrition Support on the Clinical Outcome of Postoperative Patients
Worked on OXYGEN, USP at Advanced Solutions Life Sciences? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on OXYGEN, USP offers career stability in a mature, peak-stage respiratory therapeutic with established clinical use and steady demand, but limited growth or innovation-driven advancement opportunities. Roles will emphasize operational excellence, regulatory compliance, supply chain optimization, and market maintenance rather than new drug launches or clinical expansion.